Novartis's antipsychotic Fanapt launched in the US - update
15 January 2010
Katie McQue
Please Login to read the full article.
15 January 2010
Katie McQue
katie.mcque@informa.com
Novartis has launched its twice-daily oral atypical antipsychotic Fanapt (iloperidone) in the US for the acute treatment of schizophrenia in adults.
The drug was approved by the US
FDA in May, after it was filed by...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vanda, Probiomed in deal for schizophrenia drug Fanapt for Mexico
- Zogenix, Duract in deal for work on once-monthly risperidone, to contrast with J&J blockbuster
- 2012 patent expiries will undermine pharma industry
- Vanda, Megapharm in deal for schizophrenia drug Fanapt in Israel
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
